BridgeBio Pharma, Inc.: 5%+ holders

As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of BridgeBio Pharma, Inc. The largest reported stake is Janus Henderson Group Plc's, at 6.8%. 17 filings are on record since July 1, 2025 (Schedule 13G/A, May 15, 2026).

Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies ↓

Sell to companies like BridgeBio Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-10-27 · Holder: BlackRock, Inc. · Percent: 5.1% · SCHEDULE 13G
• Filed 2026-08-17 · Holder: KKR Genetic Disorder L.P. · Percent: 4.7% · SCHEDULE 13D/A
• Filing 2026-08-03 · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 10,743,063 · Sole dispositive: 0 · Shared dispositive: 10,743,063 · SCHEDULE 13G/A, 2026-08-03
• Filed 2026-07-27 · Holder: BlackRock, Inc. · Percent: 4.96% · SCHEDULE 13G/A
• Filed 2026-07-10 · Holder: Viking Global Investors LP · Percent: 5% · SCHEDULE 13D/A

BridgeBio Pharma, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-01. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind BridgeBio Pharma, Inc. and the warning signs.

See BridgeBio Pharma, Inc.'s free Snapshot Watch BridgeBio Pharma, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on BridgeBio Pharma, Inc. and the records around it.

BridgeBio Pharma, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: ENANTA PHARMACEUTICALS INC (Aug 2026), EXELIXIS, INC. (Aug 2026), InflaRx N.V. (Aug 2026)
• Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026), Tyra Biosciences, Inc. (May 2026)
• VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)

Want the whole picture on BridgeBio Pharma, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on BridgeBio Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on BridgeBio Pharma, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies BridgeBio Pharma, Inc. by CUSIP 10806X102 and gives its principal executive office as 421 Kipling Street, PALO ALTO, CA 94301 (SCHEDULE 13G, 2026-10-27).

Purpose of Transaction (Item 4)

Viking Global Investors LP

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 12 is incorporated by reference herein.Item 4 of the SCHEDULE 13D/A filed 2026-07-10

KKR Genetic Disorder L.P.

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Sale of Common Stock On August 13, 2026, KKR Genetic Disorder L.P., as a selling stockholder, and the Issuer entered into an underwriting agreement (the ''Underwriting Agreement'') with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC (the ''Representatives''), as the representatives of the several underwriters listed on Schedule I thereto (the ''Underwriters''), relating to an offering of 5,000,000 shares of Common Stock by KKR Genetic Disorder L.P. (the ''Offering''), and purchase by the Underwriters of the shares of Common Stock, at a net price to KKR Genetic Disorder L.P. of $77.415 per share. The Offering closed on August 17, 2026. The Offering was made pursuant to the Issuer's effective shelf registration statement on Form S-3ASR (File No. 333-297701), including the prospectus, dated July 24, 2026, as supplemented by a prospectus supplement, dated August 13, 2026, filed on August 14, 2026. Pursuant to the Underwriting Agreement, KKR Genetic Disorder L.P. entered into a lock-up agreement (the ''Lock-Up Agreement'') with the Underwriters pursuant to which it has agreed with the Underwriters, subject to certain exceptions, not to dispose of or hedge any of their Common Stock or securities convertible into or exchangeable for shares of Common Stock, during the period from August 13, 2026 continuing through the date 30 days after the date of the final prospectus …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-17; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns BridgeBio Pharma, Inc.

Who owns BridgeBio Pharma, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of BridgeBio Pharma, Inc.: Janus Henderson Group Plc (6.8%, Schedule 13G/A, filed 2026-05-15), Farallon Capital Management, L.L.C. (5.5%, Schedule 13G/A, filed 2026-08-03), Dapice Joshua J. (5.2%, Schedule 13G, filed 2026-05-29), BlackRock, Inc. (5.1%, Schedule 13G, filed 2026-10-27) and Viking Global Investors LP (5%, Schedule 13D/A, filed 2026-07-10).

Who are the largest shareholders of BridgeBio Pharma, Inc.?

By the share each holder's latest filing reports, the largest holders of BridgeBio Pharma, Inc. on this page are Janus Henderson Group Plc (6.8%), Farallon Capital Management, L.L.C. (5.5%) and Dapice Joshua J. (5.2%).

When did Janus Henderson Group Plc buy into BridgeBio Pharma, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G, filed 2026-02-17, reporting 5.7%; its latest, Schedule 13G/A filed 2026-05-15, reports 6.8%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for BridgeBio Pharma, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when BridgeBio Pharma, Inc. is mentioned again
• Find former BridgeBio Pharma, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes